OIT Software Licensing is evaluating the current and prospective usage of JMP Genomics.
JMP Genomics now gives you more freedom than ever to explore your data, understand it and share analysis results with colleagues. With an elegant user interface that takes full advantage of the JMP Windows environment, JMP Genomics automatically organizes results into tabbed reports and lets you customize your view of analysis options. With capabilities for integration with R, Excel and other tools – JMP Genomics becomes your analytic hub.
Whether you’re working with large data sets from next-gen sequencing studies or microarrays, JMP Genomics provides the tools you need to analyze rare and common variants, detect differential expression patterns, discover reliable biomarker profiles, and incorporate pathway information into your analysis workflows.
JMP Genomics has been requested through our new software evaluation request form (http://oit.duke.edu/comp-print/software/request/it_request.php) for central funding/distribution, and we put together a wiki with some information on the software and some of the purchase options.
If your department currently uses this software or if you are interested in using this software or have considered purchasing this before, we invite you to visit the wiki and comment on it. The information that we collect in this manner will help us determine whether or not central funding and distribution would be beneficial to the Duke community.
Wiki: https://wiki.duke.edu/display/OITSLP/JMP+Genomics
Summary of wiki: JMP Genomics was purchased in 2009 and we attempted to recover the cost by reselling licenses. This program was unsuccessful as the price per license was too high and therefore there was not as much buy-in as expected. With the move to JMP for Academia, the cost has decreased drastically and if there is enough interest, we could try out JMP Genomics again since there is now much less risk.
OIT already centrally funds JMP, but will not be able to assume the additional cost of adding JMP Genomics to the license. The cost to add this product to our license is modest, and the cost could be recovered very easily if a few departments chip in. We could also test out a pay-by-license model (like with SAS) with little risk depending on how much individual users of JMP Genomics are willing to spend per license.
